31 October 2016 - Deborah Wilkes
Archived
GlaxoSmithKline said its powerbrands – especially Sensodyne, Voltaren and Otrivin – had helped drive worldwide sales at its Consumer Healthcare business up by 5% at constant exchange rates to £1.87 billion (US$2.33 billion) in the third quarter of 2016.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.